美国遗传学研究所在白细胞介素12（IL-12）治疗引起严重不良反应、导致1人死亡、 11人住院后,中断了用重组IL-12治疗晚期肾癌患者的Ⅱ期试验。 据该研究所称,在用IL-12治疗癌症和人类免疫缺陷症病毒（HIV）阳性患者的Ⅰ 期试验中,未见严重副作用。然而,Ⅱ期试验使用了不同的剂量和剂型。该所没有透露1例致死患者的死因和11例住院患者的细节。该所已通知美国食品和药物管理局暂时 The American Genetics Institute caused serious adverse effects in patients treated with interleukin-12 (IL-12), resulting in 1 death and 11 patients who were hospitalized, interrupting Phase II trials of patients with advanced renal cancer treated with recombinant IL-12. According to the study, no serious adverse effects were seen in Phase I trials of cancer and HIV-positive patients treated with IL-12. However, Phase II trials use different doses and dosage forms. The agency did not reveal the details of the death of one patient who died and of 11 hospitalized patients. The agency has notified the U.S. Food and Drug Administration temporarily